Towards Cure Via Only Ultra-short ICB in CSCC

Sponsor
The Netherlands Cancer Institute
Study ID
NCT06823479
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    3 mg/kg
  • Ipilumimab — DRUG
    1 mg/kg

Study Details

The goal of this clinical trial is to determine whether cutaneous squamous cell carcinoma patients can be cured using only immunotherapy, without surgery or radiotherapy.

Key Dates

Start date
May 14, 2025
Status verified
May 2025
Primary completion
Feb 28, 2029
Completion
Feb 28, 2029

Study Design

Enrollment
41 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant nivolumab + ipilimumab
    Intravenous neoadjuvant nivolumab 3 mg/kg in week 0 and 2 in combination with intravenous neoadjuvant ipilimumab 1 m/kg in week 0.

Primary Outcome Measure

Rate of clinical complete remission after only immunotherapy [ Time Frame: From the start of immunotherapy until 24 months of follow-up ]

Central Contacts

Related Studies